<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>182-DISOPYRAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DISOPYRAMIDE" rxcui="3541">
<ATC code="C01BA03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Risk of decrease of the concentrations of the disopyramide by the inducer.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possibly adjustment of the dosage of the disopyramide during the administration of these medications together and 1 to 2 weeks after the inducer is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>182-DISOPYRAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DISOPYRAMIDE" rxcui="3541">
<ATC code="C01BA03" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the disopyramide due to decrease of its metabolism.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the disopyramide</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>182-DISOPYRAMIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="DISOPYRAMIDE" rxcui="3541">
<ATC code="C01BA03" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="JOSAMYCIN" rxcui="6084">
<ATC code="J01FA07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the disopyramide: severe hypoglycemia, lengthening of the QT interval, and serious ventricular arrhythmias, especially of the torsade de pointes type.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical, biological and EKG monitoring, </COMMENT>
</INTERACTION>
</INTERACTIONS>
